Mutations in K-ras
Detected in Plasma DNA Are Not an Indicator of Disease in Patients with Non-Small Cell Lung Cancer
To the Editor:
The demonstration that cell-free circulating DNA detected in the plasma of cancer patients is genetically identical to that of the primary tumor has generated substantial interest, leading to Ͼ200 publications (http:// www.ncbi.nlm.nih.gov).
Recently, Wang et al. (1 ) reported in this journal that the method chosen for DNA isolation might contribute significantly to mutation detection (in their case, K-ras mutations in the plasma of patients with colorectal cancer). Briefly, they recommended the use of a modified guanidine/Promega resin method (G/R) to isolate DNA, affirming that this method enhances assay sensitivity. We used the same approach to detect K-ras mutations in the plasma of patients with nonsmall cell lung cancer (NSCLC) and compared the Qiagen vs the G/R method for isolation of circulating DNA. We purified DNA from plasma samples and cancer tissues from 12 patients. The DNA in 2 aliquots of the plasma from each patient was isolated by the Qiagen method (1, 2 ) and by the G/R method according to Wang et al. (1 ) . Additionally, DNA was isolated by the Qiagen method from matched plasma and tissue samples (n ϭ 10 for each) and from 76 plasma-only samples (36 from cancer patients and 40 from cancer-free volunteers) according to Kopreski et al. (2 ) . There was no difference in the number of K-ras mutations detected in the plasma samples collected from patients (n ϭ15; 41.7%) and from volunteers (n ϭ 12; 30.0%; odds ratio ϭ 1.6; P ϭ 0.21). In addition, when we evaluated the presence of K-ras mutations in the matched plasma and neoplastic tissue samples, we observed no correlation. Finally, when we compared the results (K-ras status) for DNA samples isolated from plasma by the 2 different methods with the results obtained for the DNA isolated from tissue samples (12 patients), we observed K-ras codon 12 mutations in 2 different tissue samples, whereas we detected no mutations in plasma DNA isolated with the Qiagen method and 2 mutations different from those identified in the corresponding tumor tissue in the plasma DNA isolated with the G/R method. The correlation between controls and cases was not significant ( 2 ϭ 0.7; P ϭ 0.5). The correlations between results obtained for tissue DNA and for plasma DNA isolated by the Qiagen or G/R method also were not significant (P ϭ 0.4 and P ϭ 1.0, respectively, nonparametric test for cases vs samples), nor was the correlation between the G/R and Qiagen isolation methods (P ϭ 0.2).
These data show no relationship between K-ras mutations found in DNA from plasma and tumor tissue from NSCLC patients. Our results do not support the suggestion that K-ras mutations detected in plasma DNA are markers for tumor detection.
Ramirez et al. (3 ) analyzed K-ras mutations (codon 12) in tumor and paired serum DNA of 51 NSCLC patients undergoing surgery and detected mutations in 9 tumors and 12 serum samples. As suggested by Gautschi and Ziegler (4 ) , serum may contain not only DNA of tumor origin, but also a variable fraction of DNA derived from in vivo-and in vitro-damaged hematopoietic cells. Indeed, lymphocytes stimulated with phytohemagglutinin or antigen may release DNA (5 ). Furthermore, human leukocytes stimulated by neutrophil-derived hydroxyl radicals may cause activation of K-ras codon 12 (6 ) . In addition, inhaled particles in exposed individuals can generate reactive oxygen species that can activate K-ras (7 ) . Moreover, K-ras mutations are detected in neogenetic lesions of subpleural fibrotic lesions, including ciliated bronchial epithelium and metaplastic epithelium (8 ) . Because chronic inflammation may be present in patients without cancer as well as those with cancer (9 ), the analysis of K-ras mutations in plasma may be influenced by such factors. Finally, as reported recently by Keohavong et al. (10 ) , K-ras mutations are frequently found in histologically normal tissues near tumors, suggesting that such mutations may represent an early event in the development of lung cancer. K-ras mutations thus may be present before clinically detectable tumors. As a final point, it is important to note that K-ras mutations have been detected in patients with ulcerative colitis, Crohn disease (11, 12 ) , and Helicobacter pylori-associated chronic gastritis (13 ) . We observed K-ras mutation in 2 volunteers diagnosed with chronic gastritis, in 1 patient with kidney failure, and in 2 who were heavy smokers.
In light of these observations, plasma DNA assays for the detection of mutations in codon 12 of K-ras do not provide a reliable method to screen populations for the somatic mutations frequently found in neoplasms. Further confirmatory studies are required.
